Cardiovascular diseases and androgen deprivation therapy (CROSBI ID 275395)
Prilog u časopisu | stručni rad
Podaci o odgovornosti
Boban, Marko
engleski
Cardiovascular diseases and androgen deprivation therapy
The leading cause of death in patients with prostate cancer are cardiovascular diseases. Androgen deprivation therapy is the mainstay of treatment in prostate cancers. The latter has numerous perplexed disadvantaging effects to cardiovascular health. ADT alternates the metabolic profile, insulin resistance and glucose metabolism, causes loss of lean body mass, an increase in adipose tissue, obesity, worsening of atherosclerosis and heart failure. It is important to point out that prostate cancer survivors have increased prevalence of coronary artery disease, cerebrovascular stroke, myocardial infarctions and cardiovascular mortality. Due to these reasons particular care on prevention and treatment of cardiovascular diseases should become a standard of care in patients with prostate cancer.
Prostate Cancer ; Androgen Deprivation Therapy (ADT) ; Cardiovascular Diseases ; Myocardial Infarctio
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
58 (2)
2019.
60-63
objavljeno
0353-9474
10.20471/acc.2019.58.s2.09